REDWOOD CITY, Calif., April 20, 2016 /PRNewswire/ -- ARMO BioSciences, Inc., a clinical-stage biotechnology company, today announced that two abstracts with clinical data on the Company's lead investigational drug AM0010 (PEGylated Interleukin-10) ...